Glaukos provided an investor presentation highlighting commercial progress for iDose TR, the March 2026 Epioxa launch and pipeline expansion across glaucoma, keratoconus and retina.
Key Highlights:
- Filed Exhibit 99.1 investor presentation under Regulation FD and posted it on the investor website.
- iDose TR: FDA-approved long-duration travoprost implant (re-administration approved Jan 2026) designed to deliver up to 3 years of therapy.
- Epioxa: first‑and‑only epi‑on keratoconus topical therapy, commercially available March 2026 with launch infrastructure and payer efforts underway.
- Pipeline: 13 disclosed programs, 12 commercial products, multiple iDose next‑gen assets (TRIO, TREX) in development and Phase 2/3 studies ongoing.
- Financial/operations: 2026 revenue guidance midpoint ~$690M, $289M cash and equivalents, no debt as of 6/30/2026 and 85% adjusted gross margin (2Q 2026 non‑GAAP).
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.